These companies could innovate their way to success.

Wondering whether Vertex Pharmaceuticals is still worth buying at around $452 a share, or if the big gains are already behind ...

Vertex Pharmaceuticals recently reported clinical data showing that CASGEVY helped all evaluable children aged 5–11 with ...

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

The long-term prospects for these stocks look especially bright.

Vertex Pharmaceuticals presents clinical data demonstrating benefits of Casgevy in SCD and TDT patients aged 5+ at ASH ...

The International Society for Stem Cell Research (ISSCR) today opened its sold-out international symposium, Accelerating ...

Nandkumar M. Kamat As the year is about to end, here is a short review of important breakthroughs in science that defined the ...

On November 18, 2025, ToolGen, Inc. (“ToolGen”) filed a complaint (“Complaint”) in the District of Massachusetts alleging infringement of its ...

A 9,000 percent rise since 2015 in overdose deaths involving fentanyl among adults over 65 is prompting a statewide effort to provide older adults with the information they need to age safely. An ...

CFOs, including Gunnar Wiedenfels of Warner Bros Discovery and Colette Kress of Nvidia, addressed disciplined spending, ...

Scotiabank analyst Louise Chen maintained a Buy rating on AbbVie today and set a price target of $280.00. Chen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Vertex ...